4 withdrawn. 4 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Withdrawn 4 |
Follow Dermatitis, Atopic: new trials by email Literature Review of Dermatitis, Atopic trials Research Report on Dermatitis, Atopic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab dupilumab - Severe Atopic Dermatitis (AD) | Phase 4 | Withdrawn | Regeneron Pharmaceuticals | 2025-11-11 | 2025-11-28 | |
| Investigation of Flare and Remission in Subjects With Atopic Dermatitis Cyclosporine A - Atopic Dermatitis | Phase 4 | Withdrawn | LEO Pharma | 2019-01-14 | 2024-11-07 | |
| Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy Altabax (R), Vehicle and Locoid lipocream (R) - Atopic Dermatitis | Phase 4 | Withdrawn | St. Luke's-Roosevelt Hospital Center | 2009-05-01 | 2015-05-12 | |
| Evaluation to Assess the Long Term Safety of Tacrolimus Ointment for Atopic Dermatitis Tacrolimus - Atopic Dermatitis | Phase 4 | Withdrawn | University of California, Davis | 2007-09-01 | 2015-04-07 |
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Dermatitis (4) · Genetic Diseases, Inborn (4) · Hypersensitivity (4) · Hypersensitivity, Immediate (4) · Immune System Diseases (4) · Skin Diseases (4) · Skin Diseases, Eczematous (4) · Skin Diseases, Genetic (4) · Skin and Connective Tissue Diseases (4) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1) · Skin Manifestations (1)
Cyclosporine (1) · Hydrocortisone (1) · Tacrolimus (1) · dupilumab (1) · retapamulin (1)
LEO Pharma (1) · Regeneron Pharmaceuticals (1) · St. Luke's-Roosevelt Hospital Center (1) · University of California, Davis (1)
Netherlands (1) · United States (1)
2018 (1)